department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Testosterone Par · pharmadog

pharmadog
drugs
Testosterone Par

drug

patient view →

Testim

Marketedupdated 2mo ago

by Par Pharmaceutical Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Testosterone Par

generic

testosterone

indication

Secondary (Hypogonadotropic) Hypogonadism

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 12, 2026

97 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (38)

Mar 17, 2034method-of-use (U-1616)US 11090312
Mar 17, 2034method-of-use (U-4367)US 11744838
Feb 11, 2034formulationUS 8785426
Feb 11, 2034formulationUS 8785426
Feb 11, 2034formulationUS 9295675
Feb 11, 2034formulationUS 9295675
Feb 11, 2034formulationUS 9662340
Feb 11, 2034formulationUS 9662340
Sep 27, 2027method-of-use (U-1390)US 84359441.2y
Feb 26, 2027method-of-use (U-1386)US 8419307234d
Feb 26, 2027formulationUS 8807861234d
Feb 26, 2027method-of-use (U-1390)US 9289586234d
Oct 12, 2026formulationUS 846613697d
Oct 12, 2026formulationUS 846613697d
Oct 12, 2026formulationUS 846613697d
Oct 12, 2026method-of-use (U-1103)US 846613797d
Oct 12, 2026method-of-use (U-1103)US 846613797d
Oct 12, 2026method-of-use (U-1103)US 846613797d
Oct 12, 2026method-of-use (U-1103)US 846613897d
Oct 12, 2026method-of-use (U-1103)US 846613897d
Oct 12, 2026method-of-use (U-1103)US 846613897d
Oct 12, 2026formulationUS 848692597d
Oct 12, 2026formulationUS 848692597d
Oct 12, 2026formulationUS 848692597d
Oct 12, 2026formulationUS 872905797d
Oct 12, 2026formulationUS 872905797d
Oct 12, 2026formulationUS 872905797d
Oct 12, 2026method-of-use (U-1103)US 874188197d
Oct 12, 2026method-of-use (U-1103)US 874188197d
Oct 12, 2026method-of-use (U-1103)US 874188197d
Oct 12, 2026formulationUS 875407097d
Oct 12, 2026formulationUS 875407097d
Oct 12, 2026formulationUS 875407097d
Oct 12, 2026formulationUS 875932997d
Oct 12, 2026formulationUS 875932997d
Oct 12, 2026formulationUS 875932997d
Jun 2, 2026method-of-use (U-1390)US 8993520
Jun 2, 2026method-of-use (U-1390)US 9180194

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 8

drugtestosterone54 co-mentions · 51 sources
drugVogelxo54 co-mentions · 51 sources
drugBio T54 co-mentions · 51 sources
tagRecall45 co-mentions · 44 sources
tagApproval12 co-mentions · 6 sources
drugtriamcinolone acetonide Rising10 co-mentions · 10 sources
drugTRIAMCINOLONE ACETONIDE10 co-mentions · 10 sources
drugtriamcinolone acetonide ER10 co-mentions · 10 sources

Trials studying Testim

phase2Working Out M0 Bipolar Androgen Therapyrecruitingn=69
phase2Supraphysiologic Testosterone Priming Induces Darolutamide Extended Responserecruitingn=60
phase352 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadismrecruitingn=100
phase2Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)active not recruitingn=51
phase2Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancerrecruitingn=50
phase4Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Mennot yet recruitingn=144
phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCrecruitingn=26
phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancercompletedn=36

more trials →